Form 4: Maze Therapeutics Executive Trades Shares

Harold Bernstein, President, R&D & CMO of Maze Therapeutics, reports transactions involving common stock and stock options, executed under a Rule 10b5-1 trading plan.

Summary

• Harold Bernstein, President, R&D & CMO of Maze Therapeutics, Inc., has reported several transactions related to the company's common stock and stock options.
• These transactions include the acquisition of 14,853 shares of common stock at $10.42 per share, executed under a Rule 10b5-1 trading plan adopted on September 29, 2025.
• Additionally, Bernstein disposed of 13,253 shares at a weighted average price of $25.5746 and 1,600 shares at a weighted average price of $26.3576.
• Following these transactions, Bernstein beneficially owns 1,600 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral. While the executive is selling shares, the transactions were conducted under a pre-arranged Rule 10b5-1 plan, which is a standard and compliant method for insider stock management.

Positives

• The transactions were executed under a Rule 10b5-1 trading plan, indicating a pre-determined strategy for stock sales, which can mitigate insider trading concerns.
• The acquisition of 14,853 shares at $10.42 per share suggests a potential investment or exercise of options at a favorable price.

Negatives

• Disposal of a significant number of shares (14,853 shares in total) by a key executive (President, R&D & CMO) could be perceived negatively by the market.
• The weighted average sale prices ($25.5746 and $26.3576) are considerably higher than the acquisition price ($10.42), indicating a profitable sale for the executive, but also a reduction in his direct holdings.

Risks

• The disposal of shares by a high-ranking executive might signal a lack of confidence in future stock performance, although it was conducted under a pre-established trading plan.
• The specific details of the Rule 10b5-1 plan, including the rationale for its adoption and the specific timing of transactions, are not fully elaborated in this filing.

Future Outlook

The filing does not contain forward-looking statements or guidance. It solely reports past transactions.

Management Comments

• The transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025.
• The reported prices for disposed shares are weighted averages from multiple transactions at various prices within specified ranges.
• The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The use of a Rule 10b5-1 plan is a common practice for executives to manage their stock holdings systematically and avoid potential insider trading accusations, especially in the biotechnology sector where stock prices can be volatile due to clinical trial results and regulatory approvals.

Stakeholder Impact

• Shareholders may interpret the sale of shares by a key executive, even under a 10b5-1 plan, as a potential signal of reduced confidence, though the plan itself is designed to mitigate this perception.
• Employees may also be influenced by executive trading activity, potentially affecting morale or their own investment decisions.
• Creditors and suppliers are unlikely to be directly impacted by this specific insider transaction.

Next Steps

• Continued monitoring of Harold Bernstein's beneficial ownership and any future transactions.
• Observation of Maze Therapeutics, Inc.'s stock performance and corporate developments.

Key Dates

Keywords

Form 4, SEC Filing, Insider Trading, Stock Transaction, Rule 10b5-1, Maze Therapeutics, Harold Bernstein, Common Stock, Stock Options, Beneficial Ownership